Activated Clinical Trials

This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment.

Click the study links below to learn details regarding the studies on clinicaltrials.gov. You can also search for other clinical trials on our website. For more information or questions about a study, email [email protected] or call 312-355-5112.

Protocol Title: AZUR-1: A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

Sponsor: GSK

Principal Investigator: Shikha Jain, MD

Protocol Title: Protocol Title: A022102: Randomized Phase III Trial Of mFOLFIRINOX +/- Nivolumab Vs. FOLFOX +/- Nivolumab For First-Line Treatment Of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

Sponsor: Alliance

Principal Investigator: Yolande Chen, MD

Protocol Title: S2207: Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

Sponsor: SWOG

Principal Investigator: Paul Rubinstein, MD

Protocol Title: MK-3475-057: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination With Other Investigational Agents in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Sponsor: Merck, Sharp & Dohme Corp.

Principal Investigator: Karine Tawagi, MD

Newly Activated Clinical Trials